Evaluation of Specific PET Radioligand Binding To Translocator Protein
Phase of Trial: Phase I
Latest Information Update: 22 May 2017
At a glance
- Drugs RP 52028 (Primary) ; XBD 173
- Indications Neurological disorders
- Focus Diagnostic use
- 17 Jun 2016 Status changed from suspended to completed.
- 07 May 2016 Status changed from recruiting to suspended.
- 20 Jan 2016 Change in treatment table: Dose of blocking agent Emapunil decreased from 45mg to 15mg as per ClinicalTrials.gov record.